New Drug Application Filed for Ledipasvir/Sofosbuvir Combo Tablet for Hepatitis C

A new drug application has been submitted to the FDA for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic genotype-1 hepatitis C virus infection in adults.

http://ift.tt/1lE0fuw